New Oral Obesity Drug Shows 12% Weight Loss in Trial

Millions of people struggling with weight loss may soon have an easier option that doesn't require weekly injections or special storage.

A new oral medication called aleniglipron helped patients lose up to 12% of their body weight over 36 weeks in a clinical trial involving 230 adults across 38 U.S. medical centers. The results were published in Nature Medicine.

The drug works similarly to popular injectable medications like Ozempic and Wegovy by mimicking natural hormones that reduce appetite and increase feelings of fullness. But there's a crucial difference: patients simply swallow a daily pill.

"The difference with aleniglipron is it's a small molecule, which means it's chemically made and could be taken with or without food," said Dr. Robert Kushner, professor emeritus at Northwestern University and study co-author. "Because of that you can potentially combine them with other medications."

The trial divided participants into three groups receiving different doses: 45, 90, or 120 milligrams daily. After 36 weeks, the highest dose group lost an average of 12.1% of their body weight, compared to just 0.5% in the placebo group.

Side effects were mild to moderate gastrointestinal issues that decreased over time. Only 10.4% of patients stopped treatment, and no liver problems occurred.

The Ripple Effect

Current injectable weight loss drugs face serious accessibility challenges. They require refrigeration, must be injected weekly, and face manufacturing bottlenecks that create shortages and drive up costs.

An oral pill solves these problems. It can be manufactured on a larger scale, stored at room temperature, and shipped easily to pharmacies worldwide. This could bring effective obesity treatment to rural communities, developing countries, and patients who avoid needles.

The medication could also be combined with other drugs in single pills, making treatment regimens simpler for patients managing multiple conditions. That's impossible with injectable medications.

The success paves the way for a larger phase III trial that will test the drug's effectiveness in more diverse populations. Researchers plan to slow down the dose increases even further to improve tolerability.

For the 42% of American adults living with obesity, this breakthrough represents hope for treatment that fits seamlessly into daily life.